Traws Pharma, Inc. TRAW
At closeNov 5, 2026, 4:06 PM EST
After hours · Nov 5, 4:06 PM ET
- YTD
- -80.52%
- 1 year
- -89.86%
- Market cap
- 3.38M
- Revenue (ttm)
- 226.00K
- EPS (ttm)
- -1.71
- Shares out
- 3.03M
- Forward P/E
- -0.47
- YTD return
- -80.52%
- 1-year return
- -89.86%
- Volume
- 270.09K
- Avg volume
- 581.38K
- Open
- 0.27
- Previous close
- 0.2686
- Day's range
- 0.2187 – 0.2798
- 52-week range
- 0.2187 – 3.23
- Beta
- 1.41
- Price target
- 6.00 (+2626.0%)
2Y -4.8299 (-95.64%)
Key statistics
- Enterprise value
- 99.78M
- PEG ratio
- 0.00
- Price / sales
- 168.28
- Price / book
- 0.99
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -11.32M
- Total cash
- 16.89M
- Total debt
- 0
- Return on equity
- -1096.52%
- Short % of float
- 0.43%
- 50-day average
- 4.96
- 200-day average
- 11.13
Analyst view
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -6.25 | -8.81 | -2.56 | -40.96% |
| Aug 15, 2024 | Jun 1, 2024 | 0.00 | -121.75 | — | — |
| May 15, 2024 | Mar 1, 2024 | -6.00 | -6.00 | 0.00 | 0.00% |
About Traws Pharma, Inc.
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- trawspharma.com
News
Traws Pharma Enters $50M Committed Equity Purchase Agreement With Roth Principal Investments; May Issue And Sell Up To 135,135,135 Shares Of Common Stock 
Comparing Gyre Therapeutics (NASDAQ:GYRE) and Traws Pharma (NASDAQ:TRAW) 
12 Health Care Stocks Moving In Monday's After-Market Session - 12 Health Care Stocks Moving In Friday's Pre-Market Session
Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket - 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
HC Wainwright & Co. Reiterates Neutral on Traws Pharma, Maintains $1 Price Target - Traws Pharma Q2 EPS $(0.16) Beats $(0.34) Estimate
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights 
Traws Pharma (NASDAQ:TRAW) Shares Up 4.8% – Here’s What Happened
Your note
Sign in to keep a note on TRAW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 20.01% | 605,531 | 7.61M | Sep 29, 2024 |
| Vanguard Group Inc | 0.88% | 26,722 | 335.89K | Sep 29, 2024 |
| Blackrock Inc. | 0.33% | 9,956 | 125.15K | Sep 29, 2024 |
| Bank of America Corporation | 0.07% | 2,138 | 26.87K | Sep 29, 2024 |
| Morgan Stanley | 0.02% | 729 | 9.16K | Sep 29, 2024 |
| UBS Group AG | 0.02% | 630 | 7.92K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.45% | 13,750 | 172.84K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.43% | 12,879 | 161.89K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.18% | 5,597 | 70.35K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.04% | 1,267 | 15.93K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.03% | 926 | 11.64K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 512 | 6.43K | Oct 30, 2024 |